RecruitingPhase 1NCT06843317

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before

Sponsor

Clover Biopharmaceuticals USA, LLC

Enrollment

160 participants

Start Date

Mar 21, 2025

Study Type

INTERVENTIONAL

Conditions

RSV Infection

Summary

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

Eligibility

Min Age: 60 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called AREXVY, a biological treatment called Candidate vaccine, SCB-1019T, and others for people with rsv infection. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 60 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCandidate vaccine, SCB-1019T

SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.

BIOLOGICALAREXVY

positive comparator

OTHERplacebo

Placebo Comparator